Opko Pharmaceuticals, LLC

Baker Norton Pharmaceuticals, Inc.

Baker Cummins Pharmaceuticals, Inc.

Eirgen Pharma Ltd.

Baker Cummins Dermatologicals, Inc.

Phillip Frost

Arturo Santos

Thomas Kodadek

Elliot F Hahn

Charles W Bishop

Jane Hsiao

Jack Fishman

Naveed Shams

Nadine Dejneka

Jay S Skyler

Ottrina S Bond

Jing J Lu

The present invention relates to pharmaceutical formulations comprising an anti angiogenic compound such as a monoclonal antibody or fragment thereof selected from, for example, ranibizumab, which is a vascular endothelial growth factor binder which inhibits the action of VEGF, and a delivery agent selected from a pharmaceutically acceptable liposome. The formulations are useful in the treatment of a variety of angiogenic disorders and diseases in animals and people, and, preferably, in ophthalmic disorders selected from age-related macular degeneration, diabetic macular edema and corneal neovascularization.

Liposome formulations

Methods and compositions for treating bariatric surgery patients, and for treating or preventing complications associated with such patients, are disclosed.

Use of calcifediol in bariatric surgery patients

The present invention provides for the identification of an antigen surrogate to the native antigens for the autoimmune disease pemphigus vulgaris. Ligands are discovered using large random peptoid or cyclic peptoid libraries that are screened against known antibodies to autoimmune diseases. The ligands may be useful as drugs in the treatment of such diseases and can also be used in combination with the comcomitant removal of T-cells associated with autoimmune disorders.

Antigen surrogates in autoimmune disease

The present invention provides for the identification of an antigen surrogate to the native antigens for the autoimmune disease pemphigus vulgaris. Ligands are discovered using large random peptoid or cyclic peptoid libraries that are screened against known antibodies to autoimmune diseases. The ligands may be useful as drugs in the treatment of such diseases and can also be used in combination with the concomitant removal of T-cells associated with autoimmune disorders.

Disclosed herein are siRNA compositions and methods useful for inhibiting expression of vascular endothelial growth factor (VEGF) isoforms. Such compositions and methods further involve siRNA capable of selectively targeting angiogenic VEGF isoforms while selectively sparing anti-angiogenic isoforms. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering small interfering RNAs as disclosed.

Compositions and methods for selective inhibition of VEGF

Cover for a nasal inhaler

A method of treating human or animal patients suffering from insulin resistance syndromes, particularly diabetes mellitus, by administering an effective amount of the compound magnesium vanadate. Daily dosage ranges are preferably from about 2 to about 60 mg per kg of patient body weight. Pharmaceutical compositions for use in the method of treatment include magnesium vanadate and at least one pharmaceutically acceptable inert ingredient, and may be oral, parenteral, transdermal or transmucosal dosage forms containing from about 50 to about 1000 mg of magnesium vanadate per unit.

Method and composition for treatment of insulin resistance syndromes

Novel anti-viral compounds comprise phosphate-linked dimers of anti-viral nucleoside derivatives, or salts or esters of such nucleoside dimers. Pharmaceutical compositions containing the dimers and methods of treatment utilizing the same are disclosed.

Anti-viral compounds, dosage forms and methods

A method of treating a patient suffering from mast cell disease comprising daily administration to such patient of from about 1 to about 150 mg of a pure narcotic antagonist, e.g., nalmefene or naltrexone. The antagonist may be administered in divided doses from one to four times daily, preferably by the oral route. Parenteral, transmucosal and transdermal administration may be utilized where suitable.

Method of treating mast cell disease

A method of treating human or animal patients suffering from mast cell-mediated dermatological disorders comprising the administration to the affected skin areas of a topical composition comprising from about 0.01 to about 10% by weight of the narcotic antagonist nalmefene or one of its salts or esters in a pharmaceutically inert topical vehicle. Compositions suitable for use in such methods include solutions, aerosols, creams, gels, ointments and lotions. The compositions may be applied to the affected areas from 1 to about 6 times daily.

Method for treatment of mast cell-mediated dermatologic disorders

A method of treating patients suffering from allergic rhinitis comprises the topical administration to the nasal passages of such patients of a liquid solution containing from about 0.5 to about 10% by weight of the narcotic antagonist nalmefene or a pharmaceutically acceptable salt thereof. The solution may be administered in spray form from a squeeze bottle or from a dropper. Administration of from about 10 to about 200 microliters of the solution into each nostril may be repeated from 1 to 5 times daily.

Growing community of inventors

Miami Beach, FL, United States of America

Phillip Frost